Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer

The capecitabine and oxaliplatin (CapeOX) regimen is a commonly used adjuvant chemotherapeutic regimen for gastric cancer (GC). However, some patients exhibit a poor chemotherapy response due to genetic differences among individuals. Therefore, finding an effective sensitization strategy for CapeOX...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Yuan, Zhen, Shen, Renbin, Jiang, Yannan, Xu, Wei, Gu, Menghui, Gu, Xinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530885/
https://www.ncbi.nlm.nih.gov/pubmed/33029206
http://dx.doi.org/10.3892/ol.2020.12153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530885/
https://www.ncbi.nlm.nih.gov/pubmed/33029206
http://dx.doi.org/10.3892/ol.2020.12153

Ejemplares similares